A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands
Advances in genomic analyses enable the identification of new proteins that are associated with disease. To validate these targets, tool molecules are required to demonstrate that a ligand can have a disease‐modifying effect. Currently, as tools are reported for only a fraction of the proteome, plat...
Gespeichert in:
Veröffentlicht in: | Angewandte Chemie International Edition 2020-11, Vol.59 (47), p.21096-21105 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 21105 |
---|---|
container_issue | 47 |
container_start_page | 21096 |
container_title | Angewandte Chemie International Edition |
container_volume | 59 |
creator | Grant, Emma K. Fallon, David J. Hann, Michael M. Fantom, Ken G. M. Quinn, Chad Zappacosta, Francesca Annan, Roland S. Chung, Chun‐wa Bamborough, Paul Dixon, David P. Stacey, Peter House, David Patel, Vipulkumar K. Tomkinson, Nicholas C. O. Bush, Jacob T. |
description | Advances in genomic analyses enable the identification of new proteins that are associated with disease. To validate these targets, tool molecules are required to demonstrate that a ligand can have a disease‐modifying effect. Currently, as tools are reported for only a fraction of the proteome, platforms for ligand discovery are essential to leverage insights from genomic analyses. Fragment screening offers an efficient approach to explore chemical space. Presented here is a fragment‐screening platform, termed PhABits (PhotoAffinity Bits), which utilizes a library of photoreactive fragments to covalently capture fragment–protein interactions. Hits can be profiled to determine potency and the site of crosslinking, and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is envisioned to be widely applicable to novel protein targets, identifying starting points in the development of therapeutics.
PhotoAffinity Bit (PhABit) is a photoreactive fragment‐screening platform to covalently capture fragment–protein interactions. Hits can be profiled and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is widely applicable to novel protein targets, identifying starting points in the development of therapeutics. |
doi_str_mv | 10.1002/anie.202008361 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2458744828</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2458744828</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4501-4eed27f126176d535809f57b42301ff70b3a5c83cb5727ae7f8f3d2d3708a4fb3</originalsourceid><addsrcrecordid>eNqFkMtOAjEYhRujEUS3Lk0T14O9TssSDSgJURJ13XRmWixhWuwMMex8BJ_RJ7EExKWb_5bvnD85AFxi1McIkRvtnekTRBCSNMdHoIs5wRkVgh6nmVGaCclxB5w1zSLxUqL8FHQoEYwnvgvMEM7eQhu0tc67dvP9-XWrG1PBcdTz2vg2HZ7LaIx3fg5nS93aEGuYChwlSekSAidVqi5tunXBw2DhLIbWOA-nbq591ZyDE6uXjbnY9x54HY9e7h6y6dP95G44zUrGEc6YMRURFpMci7zilEs0sFwUjFCErRWooJqXkpYFF0RoI6y0tCIVFUhqZgvaA9c731UM72vTtGoR1tGnl4owLgVjkshE9XdUGUPTRGPVKrpax43CSG1TVdtU1SHVJLja266L2lQH_DfGBAx2wIdbms0_dmr4OBn9mf8AsqKFzw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2458744828</pqid></control><display><type>article</type><title>A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Grant, Emma K. ; Fallon, David J. ; Hann, Michael M. ; Fantom, Ken G. M. ; Quinn, Chad ; Zappacosta, Francesca ; Annan, Roland S. ; Chung, Chun‐wa ; Bamborough, Paul ; Dixon, David P. ; Stacey, Peter ; House, David ; Patel, Vipulkumar K. ; Tomkinson, Nicholas C. O. ; Bush, Jacob T.</creator><creatorcontrib>Grant, Emma K. ; Fallon, David J. ; Hann, Michael M. ; Fantom, Ken G. M. ; Quinn, Chad ; Zappacosta, Francesca ; Annan, Roland S. ; Chung, Chun‐wa ; Bamborough, Paul ; Dixon, David P. ; Stacey, Peter ; House, David ; Patel, Vipulkumar K. ; Tomkinson, Nicholas C. O. ; Bush, Jacob T.</creatorcontrib><description>Advances in genomic analyses enable the identification of new proteins that are associated with disease. To validate these targets, tool molecules are required to demonstrate that a ligand can have a disease‐modifying effect. Currently, as tools are reported for only a fraction of the proteome, platforms for ligand discovery are essential to leverage insights from genomic analyses. Fragment screening offers an efficient approach to explore chemical space. Presented here is a fragment‐screening platform, termed PhABits (PhotoAffinity Bits), which utilizes a library of photoreactive fragments to covalently capture fragment–protein interactions. Hits can be profiled to determine potency and the site of crosslinking, and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is envisioned to be widely applicable to novel protein targets, identifying starting points in the development of therapeutics.
PhotoAffinity Bit (PhABit) is a photoreactive fragment‐screening platform to covalently capture fragment–protein interactions. Hits can be profiled and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is widely applicable to novel protein targets, identifying starting points in the development of therapeutics.</description><edition>International ed. in English</edition><identifier>ISSN: 1433-7851</identifier><identifier>EISSN: 1521-3773</identifier><identifier>DOI: 10.1002/anie.202008361</identifier><identifier>PMID: 32745361</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Antineoplastic Agents - analysis ; Antineoplastic Agents - pharmacology ; Bridged Bicyclo Compounds, Heterocyclic - analysis ; Bridged Bicyclo Compounds, Heterocyclic - pharmacology ; covalent ; Cross-Linking Reagents - chemistry ; Crosslinking ; Drug development ; drug discovery ; Genomic analysis ; Humans ; inhibitors ; Ligands ; Molecular Structure ; photoaffinity ; Photoaffinity Labels - chemistry ; Protein interaction ; Proteins ; Proteins - antagonists & inhibitors ; Proteins - chemistry ; Proteomes ; Pyrazoles - analysis ; Pyrazoles - pharmacology ; Quinoxalines - analysis ; Quinoxalines - pharmacology ; Screening ; Sulfonamides - analysis ; Sulfonamides - pharmacology ; Vemurafenib - analysis ; Vemurafenib - pharmacology</subject><ispartof>Angewandte Chemie International Edition, 2020-11, Vol.59 (47), p.21096-21105</ispartof><rights>2020 Wiley‐VCH GmbH</rights><rights>2020 Wiley-VCH GmbH.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4501-4eed27f126176d535809f57b42301ff70b3a5c83cb5727ae7f8f3d2d3708a4fb3</citedby><cites>FETCH-LOGICAL-c4501-4eed27f126176d535809f57b42301ff70b3a5c83cb5727ae7f8f3d2d3708a4fb3</cites><orcidid>0000-0001-7165-0092</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fanie.202008361$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fanie.202008361$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32745361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grant, Emma K.</creatorcontrib><creatorcontrib>Fallon, David J.</creatorcontrib><creatorcontrib>Hann, Michael M.</creatorcontrib><creatorcontrib>Fantom, Ken G. M.</creatorcontrib><creatorcontrib>Quinn, Chad</creatorcontrib><creatorcontrib>Zappacosta, Francesca</creatorcontrib><creatorcontrib>Annan, Roland S.</creatorcontrib><creatorcontrib>Chung, Chun‐wa</creatorcontrib><creatorcontrib>Bamborough, Paul</creatorcontrib><creatorcontrib>Dixon, David P.</creatorcontrib><creatorcontrib>Stacey, Peter</creatorcontrib><creatorcontrib>House, David</creatorcontrib><creatorcontrib>Patel, Vipulkumar K.</creatorcontrib><creatorcontrib>Tomkinson, Nicholas C. O.</creatorcontrib><creatorcontrib>Bush, Jacob T.</creatorcontrib><title>A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands</title><title>Angewandte Chemie International Edition</title><addtitle>Angew Chem Int Ed Engl</addtitle><description>Advances in genomic analyses enable the identification of new proteins that are associated with disease. To validate these targets, tool molecules are required to demonstrate that a ligand can have a disease‐modifying effect. Currently, as tools are reported for only a fraction of the proteome, platforms for ligand discovery are essential to leverage insights from genomic analyses. Fragment screening offers an efficient approach to explore chemical space. Presented here is a fragment‐screening platform, termed PhABits (PhotoAffinity Bits), which utilizes a library of photoreactive fragments to covalently capture fragment–protein interactions. Hits can be profiled to determine potency and the site of crosslinking, and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is envisioned to be widely applicable to novel protein targets, identifying starting points in the development of therapeutics.
PhotoAffinity Bit (PhABit) is a photoreactive fragment‐screening platform to covalently capture fragment–protein interactions. Hits can be profiled and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is widely applicable to novel protein targets, identifying starting points in the development of therapeutics.</description><subject>Antineoplastic Agents - analysis</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Bridged Bicyclo Compounds, Heterocyclic - analysis</subject><subject>Bridged Bicyclo Compounds, Heterocyclic - pharmacology</subject><subject>covalent</subject><subject>Cross-Linking Reagents - chemistry</subject><subject>Crosslinking</subject><subject>Drug development</subject><subject>drug discovery</subject><subject>Genomic analysis</subject><subject>Humans</subject><subject>inhibitors</subject><subject>Ligands</subject><subject>Molecular Structure</subject><subject>photoaffinity</subject><subject>Photoaffinity Labels - chemistry</subject><subject>Protein interaction</subject><subject>Proteins</subject><subject>Proteins - antagonists & inhibitors</subject><subject>Proteins - chemistry</subject><subject>Proteomes</subject><subject>Pyrazoles - analysis</subject><subject>Pyrazoles - pharmacology</subject><subject>Quinoxalines - analysis</subject><subject>Quinoxalines - pharmacology</subject><subject>Screening</subject><subject>Sulfonamides - analysis</subject><subject>Sulfonamides - pharmacology</subject><subject>Vemurafenib - analysis</subject><subject>Vemurafenib - pharmacology</subject><issn>1433-7851</issn><issn>1521-3773</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOAjEYhRujEUS3Lk0T14O9TssSDSgJURJ13XRmWixhWuwMMex8BJ_RJ7EExKWb_5bvnD85AFxi1McIkRvtnekTRBCSNMdHoIs5wRkVgh6nmVGaCclxB5w1zSLxUqL8FHQoEYwnvgvMEM7eQhu0tc67dvP9-XWrG1PBcdTz2vg2HZ7LaIx3fg5nS93aEGuYChwlSekSAidVqi5tunXBw2DhLIbWOA-nbq591ZyDE6uXjbnY9x54HY9e7h6y6dP95G44zUrGEc6YMRURFpMci7zilEs0sFwUjFCErRWooJqXkpYFF0RoI6y0tCIVFUhqZgvaA9c731UM72vTtGoR1tGnl4owLgVjkshE9XdUGUPTRGPVKrpax43CSG1TVdtU1SHVJLja266L2lQH_DfGBAx2wIdbms0_dmr4OBn9mf8AsqKFzw</recordid><startdate>20201116</startdate><enddate>20201116</enddate><creator>Grant, Emma K.</creator><creator>Fallon, David J.</creator><creator>Hann, Michael M.</creator><creator>Fantom, Ken G. M.</creator><creator>Quinn, Chad</creator><creator>Zappacosta, Francesca</creator><creator>Annan, Roland S.</creator><creator>Chung, Chun‐wa</creator><creator>Bamborough, Paul</creator><creator>Dixon, David P.</creator><creator>Stacey, Peter</creator><creator>House, David</creator><creator>Patel, Vipulkumar K.</creator><creator>Tomkinson, Nicholas C. O.</creator><creator>Bush, Jacob T.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0001-7165-0092</orcidid></search><sort><creationdate>20201116</creationdate><title>A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands</title><author>Grant, Emma K. ; Fallon, David J. ; Hann, Michael M. ; Fantom, Ken G. M. ; Quinn, Chad ; Zappacosta, Francesca ; Annan, Roland S. ; Chung, Chun‐wa ; Bamborough, Paul ; Dixon, David P. ; Stacey, Peter ; House, David ; Patel, Vipulkumar K. ; Tomkinson, Nicholas C. O. ; Bush, Jacob T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4501-4eed27f126176d535809f57b42301ff70b3a5c83cb5727ae7f8f3d2d3708a4fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antineoplastic Agents - analysis</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Bridged Bicyclo Compounds, Heterocyclic - analysis</topic><topic>Bridged Bicyclo Compounds, Heterocyclic - pharmacology</topic><topic>covalent</topic><topic>Cross-Linking Reagents - chemistry</topic><topic>Crosslinking</topic><topic>Drug development</topic><topic>drug discovery</topic><topic>Genomic analysis</topic><topic>Humans</topic><topic>inhibitors</topic><topic>Ligands</topic><topic>Molecular Structure</topic><topic>photoaffinity</topic><topic>Photoaffinity Labels - chemistry</topic><topic>Protein interaction</topic><topic>Proteins</topic><topic>Proteins - antagonists & inhibitors</topic><topic>Proteins - chemistry</topic><topic>Proteomes</topic><topic>Pyrazoles - analysis</topic><topic>Pyrazoles - pharmacology</topic><topic>Quinoxalines - analysis</topic><topic>Quinoxalines - pharmacology</topic><topic>Screening</topic><topic>Sulfonamides - analysis</topic><topic>Sulfonamides - pharmacology</topic><topic>Vemurafenib - analysis</topic><topic>Vemurafenib - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grant, Emma K.</creatorcontrib><creatorcontrib>Fallon, David J.</creatorcontrib><creatorcontrib>Hann, Michael M.</creatorcontrib><creatorcontrib>Fantom, Ken G. M.</creatorcontrib><creatorcontrib>Quinn, Chad</creatorcontrib><creatorcontrib>Zappacosta, Francesca</creatorcontrib><creatorcontrib>Annan, Roland S.</creatorcontrib><creatorcontrib>Chung, Chun‐wa</creatorcontrib><creatorcontrib>Bamborough, Paul</creatorcontrib><creatorcontrib>Dixon, David P.</creatorcontrib><creatorcontrib>Stacey, Peter</creatorcontrib><creatorcontrib>House, David</creatorcontrib><creatorcontrib>Patel, Vipulkumar K.</creatorcontrib><creatorcontrib>Tomkinson, Nicholas C. O.</creatorcontrib><creatorcontrib>Bush, Jacob T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Angewandte Chemie International Edition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grant, Emma K.</au><au>Fallon, David J.</au><au>Hann, Michael M.</au><au>Fantom, Ken G. M.</au><au>Quinn, Chad</au><au>Zappacosta, Francesca</au><au>Annan, Roland S.</au><au>Chung, Chun‐wa</au><au>Bamborough, Paul</au><au>Dixon, David P.</au><au>Stacey, Peter</au><au>House, David</au><au>Patel, Vipulkumar K.</au><au>Tomkinson, Nicholas C. O.</au><au>Bush, Jacob T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands</atitle><jtitle>Angewandte Chemie International Edition</jtitle><addtitle>Angew Chem Int Ed Engl</addtitle><date>2020-11-16</date><risdate>2020</risdate><volume>59</volume><issue>47</issue><spage>21096</spage><epage>21105</epage><pages>21096-21105</pages><issn>1433-7851</issn><eissn>1521-3773</eissn><abstract>Advances in genomic analyses enable the identification of new proteins that are associated with disease. To validate these targets, tool molecules are required to demonstrate that a ligand can have a disease‐modifying effect. Currently, as tools are reported for only a fraction of the proteome, platforms for ligand discovery are essential to leverage insights from genomic analyses. Fragment screening offers an efficient approach to explore chemical space. Presented here is a fragment‐screening platform, termed PhABits (PhotoAffinity Bits), which utilizes a library of photoreactive fragments to covalently capture fragment–protein interactions. Hits can be profiled to determine potency and the site of crosslinking, and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is envisioned to be widely applicable to novel protein targets, identifying starting points in the development of therapeutics.
PhotoAffinity Bit (PhABit) is a photoreactive fragment‐screening platform to covalently capture fragment–protein interactions. Hits can be profiled and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is widely applicable to novel protein targets, identifying starting points in the development of therapeutics.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32745361</pmid><doi>10.1002/anie.202008361</doi><tpages>10</tpages><edition>International ed. in English</edition><orcidid>https://orcid.org/0000-0001-7165-0092</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1433-7851 |
ispartof | Angewandte Chemie International Edition, 2020-11, Vol.59 (47), p.21096-21105 |
issn | 1433-7851 1521-3773 |
language | eng |
recordid | cdi_proquest_journals_2458744828 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Antineoplastic Agents - analysis Antineoplastic Agents - pharmacology Bridged Bicyclo Compounds, Heterocyclic - analysis Bridged Bicyclo Compounds, Heterocyclic - pharmacology covalent Cross-Linking Reagents - chemistry Crosslinking Drug development drug discovery Genomic analysis Humans inhibitors Ligands Molecular Structure photoaffinity Photoaffinity Labels - chemistry Protein interaction Proteins Proteins - antagonists & inhibitors Proteins - chemistry Proteomes Pyrazoles - analysis Pyrazoles - pharmacology Quinoxalines - analysis Quinoxalines - pharmacology Screening Sulfonamides - analysis Sulfonamides - pharmacology Vemurafenib - analysis Vemurafenib - pharmacology |
title | A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T13%3A24%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Photoaffinity%E2%80%90Based%20Fragment%E2%80%90Screening%20Platform%20for%20Efficient%20Identification%20of%20Protein%20Ligands&rft.jtitle=Angewandte%20Chemie%20International%20Edition&rft.au=Grant,%20Emma%20K.&rft.date=2020-11-16&rft.volume=59&rft.issue=47&rft.spage=21096&rft.epage=21105&rft.pages=21096-21105&rft.issn=1433-7851&rft.eissn=1521-3773&rft_id=info:doi/10.1002/anie.202008361&rft_dat=%3Cproquest_cross%3E2458744828%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2458744828&rft_id=info:pmid/32745361&rfr_iscdi=true |